By a 14-0 vote, CDC’s vaccine advisors endorsed the use of the mpox vaccine for high-risk adults even after the outbreak.

The Advisory Committee on Immunization Practices (ACIP) recommended the two-dose Jynneos vaccine for mpox prevention in adults at risk for infection.

Vaccine effectiveness estimates with the recommended two-dose Jynneos vaccine (given 28 days apart) range from 66% to 89%. The vaccine is currently approved for both smallpox and mpox.

According to the CDC, since the outbreak began in 2022, there have been more than 30,000 mpox cases reported and at least 54 death associated with the virus in the US. The current average is about one new case per day.

Read the full article here.